5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency

      , ,

      Signal Transduction and Targeted Therapy

      Nature Publishing Group UK

      Vaccines, Infectious diseases

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The spike protein of SARS-CoV-2 is the target of antibodies in convalescent and vaccine sera, and 23 mutations in spike protein were reported in the variants B.1.1.7, B.1.351, and P.1 (Fig. 1a). Recently, several groups evaluated the effects of convalescent and mRNA vaccine sera on two major circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 (Fig. 1b), 1–5 which leads to concerns about the immune escape of these variants from the human acquired immunity stimulated by previous infections and mRNA vaccines. Fig. 1 A schematic illustration of SARS-CoV-2 S protein sequence, prevalent mutations in current circulating SARS-CoV-2 variants, and the neutralization efficiency change of two mRNA vaccines—vaccine AZD1222 and vaccine BNT162b2. a RBM sequence (amino acid 437–508) containing N439K, E484K, and N501Y is a highly variable region, and SARS-CoV-2 spike protein mutations of three major circulating variants B.1.1.7, B.1.351, and P.1 are displayed, which can be tracked online (https://covariants.org/, https://cov-lineages.org/). b The neutralization efficiency of two major vaccines—vaccine AZD1222 and vaccine BNT162b2 to major circulating variants and potentially important variants of SARS-CoV-2 are exhibited. The neutralizing activity of the vaccine sera against different variants are shown in different colors from light red (no sufficient decrease), lycopene (decrease between 1.5-fold and 2.5-fold), to wine red (decrease more than 2.5-fold) By 27 March 2021, COVID-19 has caused more than 126.1 million infections and 2,768,409 deaths (https://coronavirus.jhu.edu/), and some countries have already developed vaccines against SARS-CoV-2. Different from the inactivated vaccines approved in China, the western countries are prone to develop mRNA vaccines or viral vector vaccines (e.g., Oxford-AstraZeneca vaccine ChAdOx1 nCoV-19 (AZD1222) and Pfizer-BioNTech vaccine BNT162b2), targeting the spike protein, whose mutations deserve consistent monitoring. Because of the instability of SARS-CoV-2 RNA and error-prone replication, viral mutations appear frequently. 1,2 Until now, 114, 67, and 36 countries have reported the discovery of variants B.1.1.7, B.1.351, and P.1, respectively (cov-lineages.org/global_report.html). Given these mutations may cause higher viral load and longer infection duration in the infected persons, 3 the effects of B.1.1.7 and B.1.351 variants on virus infection and vaccine efficiency were studied by several groups, respectively (Fig. 1b). 1,2,4,5 Supasa, P. et al. analyzed 180,000 sequences from the COG-UK database (https://www.cogconsortium.uk) and found that B.1.1.7 strain with amino acid 69 and 70 of spike protein deletion (Δ69/70) occupied the dominant position among the three subgroups (the other subgroups lack this deletion), which indicated selective advantages existed in the variation process of SARS-CoV-2. 1 And N501Y mutation existing in all B.1.1.7, B.1.351, and P.1 variants were found to enhance the affinity between receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) by about 7-fold compared with wild type (WT). According to the data released by Public Health England, the infectivity of B.1.1.7 variant is 30–50% higher than that of the wild type (WT), which may result from the increased affinity between RBD and ACE2. 3 Then the neutralization activities of 20 potent monoclonal antibodies for WT were detected by focus reduction neutralization tests, and a remarkable neutralization activity reduction was found in IGHV3-53 mAbs (e.g., mAb269 almost completely lost neutralization activity and mAb278 only retained 78% activity at most). In addition, the authors tested the efficacy of neutralizing antibodies in vaccine sera. The vaccine AZD1222 sera at 14 and 28 days following the second dose, and the vaccine BNT162b2 sera at 7–17 days following the second dose were tested, and the neutralizing activity of vaccine AZD1222 and BNT162b2 against the B.1.1.7 variant decreased by 2.5-fold and 3.3-fold, respectively. However, the cocktail therapy is still effective for neutralizing B.1.1.7 variant. Moreover, the convalescent sera from 13 B.1.1.7 patients can neutralize both B.1.1.7 variant and Victoria variant, indicating the potential of B.1.1.7 as the seed strain for future inactivated vaccines. Given the above information, the author hold the opinion that the current vaccines being arranged to massive scales against COVID-19 is still robust and no obvious evidence is found for immune escape. 1 Almost at the same time, Peiyong Shi and colleagues estimated the neutralizing efficiency of BNT162b2 vaccine sera on N501Y mutants and B.1.351 variants. 4,5 Based on the SARS-CoV-2 reverse genetic system developed previously, they obtained the variants using the SARS-CoV-2 USA-WA1/2020 strain, a isolate identified in January 2020: (1) N501Y; (2) Δ69/70 + N501Y + D614G; (3) E484K + N501Y + D614G; (4)Δ242-244 + D614G; (5) K417N + E484K + N501Y + D614G; (6) B.1.351-spike. 4,5 The ratios of the neutralization geometric mean titers (GMTs) of the sera against above mutants to their GMTs against the USA-WA1/2020 virus were 1.46, 1.41, 0.81, 0.97, 0.66, and 0.37, respectively (Fig. 1b), which again implied that E484 and K417 are key sites for virus immune escape. 4,5 Due to the continuous mutations of SARS-CoV-2 spike protein, mRNA vaccines might fail to have the potent efficiency as previously expected, suggesting viable methods (for instance, cocktail mRNA vaccines) are needed to be proposed to develop the effective mRNA vaccine. Thomson et al. found that receptor-binding motif (RBM) sequence is a highly variable region, which contained N501Y mutation in both variants B.1.1.7 and B.1.351 mentioned above. 2 And another mutation N439K, the second most prevalent mutation of spike protein also located in the RBM sequence (Fig. 1a), has been predicted to cause about 2–15 million infections worldwide according to a statistical model. 2 N439K has been deemed to increase the viral load about 1.54-fold in 1918 Scottish patients, owing to the higher affinity between RBD and hACE2. 2 Then, the recognition of N439K RBD by immune serum from 442 recovered individuals (6 patients were infected by N439K mutants) as well as 140 monoclonal antibodies from COVID-19 patients (including REGN-CoV, which obtained the EUA of FDA) were evaluated, 6.8% of the serum samples and 16.7% of mAbs had more than 2-fold reduction in binding activity, respectively. Interestingly, a camelid nanobody VHH-72 showed an increased neutralization on N439K variant, suggesting the mutation may be a double-edged sword for maintaining fitness of the N439K variants. 2 In summary, these recent studies evaluated the major circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 by convalescent and vaccine sera, and highlighted the importance of continuous SARS-CoV-2 molecular surveillance. Meantime, these researches are significant for the guidance of COVID-19 therapy, vaccine redesigning, and epidemic prevention: (1) For the COVID-19 patients, a personalized COVID-19 antibody therapy or cocktail therapy will be beneficial from the local circulating variants screening; (2) Desirable vaccine candidates, multivalent vaccines or cocktail vaccines should be designed to neutralize all circulating variants; (3) Inactivated vaccine seed strain of circulating SARS-CoV-2 variants is worthy of development for future epidemic prevention.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: found
          • Article: not found

          Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

          SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S, and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild-type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the FDA, and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Public health actions to control new SARS-CoV-2 variants

            Recent reports suggest that some SARS-CoV-2 genetic variants, such as B.1.1.7, may be more transmissible, and are quickly spreading around the world. As the emergence of more transmissible variants may exacerbate the pandemic, we provide public health guidance for increased surveillance and measures to reduce community transmission.
              Bookmark

              Author and article information

              Contributors
              fanhuahao@mail.buct.edu.cn
              Journal
              Signal Transduct Target Ther
              Signal Transduct Target Ther
              Signal Transduction and Targeted Therapy
              Nature Publishing Group UK (London )
              2095-9907
              2059-3635
              10 April 2021
              10 April 2021
              2021
              : 6
              Affiliations
              GRID grid.48166.3d, ISNI 0000 0000 9931 8406, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, , Beijing University of Chemical Technology, ; Beijing, China
              Article
              592
              10.1038/s41392-021-00592-6
              8035603
              © The Author(s) 2021

              Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

              Funding
              Funded by: FundRef https://doi.org/10.13039/501100002855, Ministry of Science and Technology of the People’s Republic of China (Chinese Ministry of Science and Technology);
              Award ID: 2020YFA0712102
              Award Recipient :
              Funded by: FundRef https://doi.org/10.13039/501100007302, Beijing University of Chemical Technology (BUCT);
              Award ID: BUCTZY2022
              Award Recipient :
              Funded by: H&H Global Research and Technology Center (grant No. H2021028)
              Categories
              Research Highlight
              Custom metadata
              © The Author(s) 2021

              vaccines, infectious diseases

              Comments

              Comment on this article